Skip to Content
Merck
CN
  • Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.

Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.

International journal of radiation oncology, biology, physics (2014-08-12)
Alexandra Deviers, Soléakhéna Ken, Thomas Filleron, Benjamin Rowland, Andrea Laruelo, Isabelle Catalaa, Vincent Lubrano, Pierre Celsis, Isabelle Berry, Giovanni Mogicato, Elizabeth Cohen-Jonathan Moyal, Anne Laprie
ABSTRACT

Because lactate accumulation is considered a surrogate for hypoxia and tumor radiation resistance, we studied the spatial distribution of the lactate-to-N-acetyl-aspartate ratio (LNR) before radiation therapy (RT) with 3D proton magnetic resonance spectroscopic imaging (3D-(1)H-MRSI) and assessed its impact on local tumor control in glioblastoma (GBM). Fourteen patients with newly diagnosed GBM included in a phase 2 chemoradiation therapy trial constituted our database. Magnetic resonance imaging (MRI) and MRSI data before RT were evaluated and correlated to MRI data at relapse. The optimal threshold for tumor-associated LNR was determined with receiver-operating-characteristic (ROC) curve analysis of the pre-RT LNR values and MRI characteristics of the tumor. This threshold was used to segment pre-RT normalized LNR maps. Two spatial analyses were performed: (1) a pre-RT volumetric comparison of abnormal LNR areas with regions of MRI-defined lesions and a choline (Cho)-to- N-acetyl-aspartate (NAA) ratio ≥ 2 (CNR2); and (2) a voxel-by-voxel spatial analysis of 4,186,185 voxels with the intention of evaluating whether pre-RT abnormal LNR areas were predictive of the site of local recurrence. A LNR of ≥ 0.4 (LNR-0.4) discriminated between tumor-associated and normal LNR values with 88.8% sensitivity and 97.6% specificity. LNR-0.4 voxels were spatially different from those of MRI-defined lesions, representing 44% of contrast enhancement, 64% of central necrosis, and 26% of fluid-attenuated inversion recovery (FLAIR) abnormality volumes before RT. They extended beyond the overlap with CNR2 for most patients (median: 20 cm(3); range: 6-49 cm(3)). LNR-0.4 voxels were significantly predictive of local recurrence, regarded as contrast enhancement at relapse: 71% of voxels with a LNR-0.4 before RT were contrast enhanced at relapse versus 10% of voxels with a normal LNR (P<.01). Pre-RT LNR-0.4 in GBM indicates tumor areas that are likely to relapse. Further investigations are needed to confirm lactate imaging as a tool to define additional biological target volumes for dose painting.

MATERIALS
Product Number
Brand
Product Description

Supelco
L-Aspartic acid, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L-Aspartic acid, BioUltra, ≥99.5% (T)
SAFC
L-Aspartic acid
Sigma-Aldrich
Lactic acid, natural, ≥85%
Sigma-Aldrich
Lactic acid, 85%, FCC
Sigma-Aldrich
N-Acetyl-L-aspartic acid, ≥99.0% (T)
Sigma-Aldrich
Lactic acid, meets USP testing specifications
Sigma-Aldrich
DL-Aspartic acid, ≥99% (TLC)
Sigma-Aldrich
L-Aspartic acid, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
L-Aspartic acid, BioXtra, ≥99% (HPLC)
Sigma-Aldrich
L-Aspartic acid, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Supelco
L-Aspartic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Lactic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Aspartic acid, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Lactic acid solution, ACS reagent, ≥85%
USP
Choline chloride, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Choline chloride, BioUltra, ≥99.0% (AT)
Sigma-Aldrich
DL-Lactic acid, ~90% (T)
Sigma-Aldrich
DL-Lactic acid, 85 % (w/w), syrup
Sigma-Aldrich
Creatine, anhydrous
Sigma-Aldrich
Choline chloride, ≥98%
Sigma-Aldrich
Choline chloride, ≥99%
Sigma-Aldrich
Choline chloride, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥98%
USP
Lactic acid, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Choline chloride, Vetec, reagent grade, ≥98%
Supelco
Choline chloride, Pharmaceutical Secondary Standard; Certified Reference Material